(Hypertension. 1999;33:1453-1457.)
© 1999 American Heart Association, Inc.
Scientific Contribution |
Intravascular Source of Adenosine During Forearm Ischemia in Humans
Implications for Reactive Hyperemia
From the Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tenn.
Correspondence to Italo Biaggioni, MD, Clinical Research Center, AA3228 MCN, Vanderbilt University, Nashville, TN 37232-2195. E-mail italo.biaggioni{at}mcmail.vanderbilt.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—It is believed that adenosine is released in ischemic tissues and contributes to reactive hyperemia. We tested this hypothesis in the human forearm using microdialysis to estimate interstitial and intravascular levels of adenosine and caffeine withdrawal to potentiate endogenous adenosine and determine its effect on reactive hyperemia. Forearm blood flow response to ischemia was measured by air plethysmography before and 60 hours after the last dose of caffeine (250 mg TID for 7 days, n=6). Forearm blood flow increased by 274±66% and 467±97% after 3 minutes of forearm ischemia, before and during caffeine withdrawal, respectively (P<0.05). Thus, caffeine withdrawal enhances reactive hyperemia. To determine the source of adenosine, we measured interstitial adenosine with the use of a microdialysis probe inserted into the flexor digitorum superficialis muscle of the forearm, and we measured intravascular adenosine with the use of a microdialysis probe inserted retrogradely into the medial cubital vein. Dialysate samples were collected at 15-minute intervals during resting, forearm ischemia, and recovery periods. Forearm ischemia failed to increase muscle dialysate concentrations of adenosine but did increase intravascular dialysate adenosine 2.1-fold, from 0.61±0.12 to 1.28±0.39 µmol/L (P<0.01, n=8). Intravascular dialysate concentrations of thromboxane B2 did not increase during ischemia, ruling out platelet aggregation as a source of adenosine. These results support the hypothesis that endogenous adenosine contributes to reactive hyperemia and indicate that the major source of adenosine in the human forearm is intravascular. We speculate that endothelial cells are the source of intravascular adenosine during ischemia.
Key Words: adenosine • ischemia • muscle • microdialysis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Local vasodilation is an important protective response to ischemia. This reactive hyperemia, present in all vascular beds with the exception of the kidneys, is largely due to metabolic factors produced by the mismatch between oxygen supply and metabolic demand. Adenosine has been identified as one of the metabolic products involved in this process. The contribution of adenosine to reactive hyperemia has been extensively studied in coronary circulation,1 and adenosine has also been proposed to contribute to blood flow regulation in several other vascular beds, including skeletal muscle.2 3 4
Because the actions of adenosine are mediated by cell membrane receptors, its importance in modulating reactive hyperemia will be proportional to the extracellular concentrations it reaches during ischemia. Adenosine is released in tissues when metabolic demands exceed oxygen supply, but extracellular concentrations are limited by efficient mechanisms of cellular uptake and metabolism. Cellular uptake is particularly potent in humans and accounts for the extremely short half-life of adenosine in blood, estimated at <1 second.5 Previous attempts to assess how much of an increase in extracellular adenosine is produced by ischemia in humans have relied on sampling from the venous drainage of the organ of interest. This, however, has 2 serious limitations. First, the very short half-life of adenosine in human blood and the likelihood that adenosine is released during sampling by activated platelets or hemolized red blood cells introduces errors that underestimate or overestimate, respectively, blood levels of adenosine, even when blood is drawn directly into a cocktail of enzyme inhibitors. Second, it is clear that the endothelium functions as an impermeable metabolic barrier for adenosine.6 Therefore, it is possible that little if any of the adenosine released into the interstitium will reach the vascular compartment.
An alternative approach to estimating adenosine concentrations is based on the microdialysis technique: a microdialysis probe is inserted into the tissue of interest and interstitial components are dialyzed and sampled. This method has the advantage that, once inside the dialysis probe, adenosine is protected from cellular reuptake or degrading enzymes. In the present study we used this approach to test the hypothesis that adenosine is increased in skeletal muscle interstitium during ischemia in humans. We also used microdialysis to estimate intravascular concentrations of adenosine in humans. Finally, to confirm the contribution of adenosine to reactive hyperemia in our model, we determined the effect of caffeine withdrawal on reactive hyperemia of the forearm, taking advantage of our previous findings that the actions of adenosine are enhanced during withdrawal of long-term caffeine consumption in humans.7
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
We studied a total of 28 healthy volunteers of both genders, 18 to 42 years of age. Subjects were asked to abstain from methylxanthines for at least 72 hours before the study day. The protocol was approved by the Vanderbilt University Institutional Review Board. Volunteers were informed of the characteristics of the study and gave written consent, in accordance with institutional guidelines.
Instrumentation
For each study session, subjects fasted and were placed in the
supine position. FBF was determined by venous occlusion air
plethysmography as previously described.8 For
intramuscular microdialysis, we used a probe with a dialysis membrane
(10x0.5 mm, 20 000 molecular weight cutoff) attached to the end
of a double-lumen cannula (CMA/20, CMA). The perfusate
enters the probe through the inner cannula, passes down to the tip of
the probe, streams upward in the space between the inner cannula and
the outer dialysis membrane, and leaves the probe through the outer
cannula via a sidearm from which it is collected. The probe was
introduced into the flexor digitorum superficialis muscle of the
nondominant forearm using 2% lidocaine for local
anesthesia. A steel guide cannula covered by a Teflon
sheath was inserted at a 45° angle, 15 mm into the muscle. The
guide cannula was then removed, leaving only the Teflon sheath in the
tissue, through which the microdialysis probe was gently introduced.
The Teflon sheath was removed by splitting it as it was retracted. The
inlet tubing of the probe was connected to a microinjection pump (CMA)
and continuously perfused with isotonic saline at 2 µL/min
(perfusate). The effluent (dialysate) was collected
continuously.
A larger probe with a greater dialysis surface (30x0.5 mm) was used for intravenous microdialysis (CMA/60). Lidocaine 2% was administered subcutaneously and a stainless steel introducer containing the microdialysis probe was inserted retrogradely into the medial cubital vein of the nondominant forearm. The introducer was then pulled out and the probe was secured with transparent surgical tape. The probe was perfused as described above.
Experimental Protocols
Protocol 1: FBF During Caffeine Withdrawal
Six subjects were given 250 mg TID caffeine for 7 days and
studied before caffeine was started (day 0) and 60 hours after the last
dose of caffeine (day 10). On each study day, subjects were
instrumented for FBF measurements as described above and were then
allowed to rest for 20 to 30 minutes. We measured the increase in FBF
produced by 15, 30, 45, 60, 90, 120, and 180 seconds of forearm
ischemia which was induced in the left arm by inflating the
proximal pneumatic cuff to 50 mm Hg above the systolic
blood pressure. Three of these subjects underwent a similar protocol
but received placebo instead of caffeine with the use of a double-blind
crossover design. Caffeine and placebo capsules were prepared by the
Department of Pharmaceutical Services, Vanderbilt University Medical
Center. The analysis of the FBF tracings was done by
investigators blinded to the treatment received (placebo or caffeine)
and to the study day (day 0 or day 10).
Protocol 2: Intramuscular Microdialysis and Forearm
Ischemia
In 14 subjects, an intramuscular probe was inserted as described
previously. After a 1-hour equilibration period, 2 consecutive
15-minute dialysate samples were collected to determine baseline
adenosine levels. Circulatory arrest (ischemia) was
induced by inflating a proximal pneumatic cuff to 50 mm Hg above
the systolic blood pressure for 15 minutes and a dialysate
sample was collected during this period. Immediately after the cuff was
deflated, 2 15-minute recovery samples were collected. The
dialysate collection period was shifted by 1 minute in relation to the
ischemic period to account for the lag time produced by the
length of the collecting tubing.
Protocol 3: Intravenous Microdialysis During
Forearm Ischemia
In 8 subjects, an intravascular probe was inserted as described
previously. After a 1-hour equilibration period, 2 consecutive
15-minute dialysate samples were collected to determine baseline
adenosine levels. Circulatory arrest (ischemia) was
induced by inflating a proximal pneumatic cuff to 50 mm Hg above
the systolic blood pressure for 15 minutes and a dialysate
sample was collected during this period. Immediately after the cuff was
deflated, two 15-minute recovery samples were collected. In 5 of
these subjects, we repeated the intravascular microdialysis protocol on
a different day to measure intravascular thromboxane
B2 concentrations.
Protocol 4: In Vitro Calibration of Microdialysis Probes
In vitro calibration of the microdialysis probe was performed in
8 subjects participating in the intramuscular microdialysis protocol
and in 5 subjects participating in the intravenous
microdialysis protocol to estimate the fraction of adenosine
recovered across the microdialysis membrane. The probe was removed from
the muscle or vein at the end of the study and was placed in a solution
containing 2.5 µmol/L adenosine. This probe was
continuously perfused with saline at 2 µL/min. The dialysate was
collected over 30 minutes in two 15-minute fractions. Two 30 µL
samples were also collected directly from the 2.5 µmol/L
adenosine solution. These 2 sets of samples were processed and
the percentage recovery was calculated by dividing the dialysate
concentration by the adenosine concentration measured from the
2.5 µmol/L adenosine solution.
Analytical and Statistical Methods
FBF was measured from the original tracings with a digitizer
tablet coupled to Sigma Scan software (Jandel Scientific) and was
expressed in units of ml/100 mL of forearm volume/min. We averaged the
first 10 blood flow determinations immediately after each intervention.
This average, an estimate of circulatory debt repayment, was used to
assess the magnitude of reactive hyperemia. We also used the
single largest blood flow during each intervention to analyze
peak blood flow.
Samples for adenosine determinations were analyzed with the use of a microbore high pressure liquid chromatography system (Isco microLC system, Isco Inc) with the use of a method previously described.9 Dialysate samples were collected in ice-cooled 200 µL polyethylene vials containing 15 µL of internal standard (2-methyl-adenosine, 20 ng/15 µL), using a fraction collector (CMA) for the intramuscular protocol and manual collection for the intravenous protocol. Samples for adenosine determinations were immediately dried by centrifugation under vacuum (Savant SpeedVac, Savant Instruments Inc) and then stored at -20°C until analyzed. The dried samples were reconstituted in 4 µL of mobile phase immediately before 1 µL was injected into the column. A standard curve was constructed for each experiment with increasing amounts of authentic adenosine and processed in a manner identical to the corresponding samples, including evaporation to dryness.
Samples for thromboxane B2 were stored at -70°C until analysis, with a modification of a previously described method.10 Briefly, 2 ng of tetradeuterated thromboxane B2 was introduced into 100 µL of each sample as an internal standard. Samples were acidified with 0.5% formic acid and extracted with ethyl acetate. After concentration, carbonyl and carboxylic acid functions were converted to the corresponding methoxime and pentafluorobenzyl esters, respectively, and purified by thin-layer chromatography. After extraction from silica, free hydroxyl groups underwent tri- methylsilylation. Samples were then concentrated under vacuum and suspended in decane. Gas chromatography was performed using a 15 M. SPB-1 fused silica capillary column. The mass spectrometer was operated in the selected ion monitoring mode scanning m/z 614 and 618 for the endogenously generated compound and internal standard, respectively.
Results are expressed as mean±SEM. Baseline values from microdialysis experiments were taken as the average of two 15-minute measurements. We used ANOVA with repeated measures within subjects for multiple comparisons. Linear regression analysis was used for construction of standard curves and calculation of samples. Data were analyzed with the use of the Number Cruncher Statistical System (NCSS). Values of P<0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effect of Caffeine Withdrawal on Reactive Hyperemia
The increase in FBF produced by ischemia was significantly greater when subjects were studied during caffeine withdrawal versus baseline (P<0.01, n=6, Figure 1). FBF increased in response to 3 minutes of ischemia from 2.4±0.5 to 7.61±0.82 mL/100 mL forearm volume/min (274±66%) at baseline (day 0), and from 2.25±0.3 to 11.45±0.88 mL/100 mL forearm volume/min (467±97%, P<0.05) during caffeine withdrawal (day 10). This potentiation was particularly apparent at peak blood flow (Figure 1). By comparison, no differences in reactive hyperemia were found in the control group of subjects receiving placebo instead of caffeine; FBF increased by 333±95% in response to 3 minutes of ischemia at baseline (day 0), and by 325±128% during placebo withdrawal (day 10, n=3).
|
Effect of Ischemia on Intramuscular and Intravascular
Adenosine
Dialysate concentrations of adenosine were high
immediately after the insertion of the intramuscular microdialysis
probe (0.97±0.23 µmol/L), but levels decreased to a stable
baseline within 1 hour. For this reason, baseline collections were
started at least 1 hour after probe insertion. Adenosine
dialysate concentrations were not significantly different during
forearm ischemia (0.28±0.08 µmol/L) versus either
baseline period (0.22±0.03 and 0.24±0.03 µmol/L, Figure 2). A slight but not significant increase
in adenosine dialysate concentrations occurred during the
recovery periods after ischemia (0.34±0.09 and 0.29±0.05
µmol/L). In vitro recovery for adenosine from the
intramuscular microdialysis probe averaged 34±6%.
|
Dialysate adenosine concentrations were stable immediately after insertion of the intravascular probe, but collection for baseline intravenous adenosine concentrations was also started at least 1 hour after probe insertion, to reproduce the intramuscular protocol. Adenosine dialysate concentrations increased significantly during forearm ischemia, from 0.61±0.12 to 1.28±0.39 µmol/L (120±43%, P<0.01, n=8, Figure 2) and returned to baseline thereafter. In vitro recovery for adenosine from the intravascular probe averaged 81±8%. The higher recovery of adenosine is explained by the 3-fold larger surface area of the intravascular probe compared with the intramuscular probe. No significant increase in thromboxane dialysate concentrations was observed during forearm ischemia. Conversely, a decrease from 0.45±0.11 to 0.27±0.01 pg/L was observed (Figure 3).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
A new and unexpected finding from this study is that ischemia does not increase interstitial muscle adenosine in the human forearm. There is ample evidence that adenosine is released from virtually any metabolically active tissue during ischemic conditions to act as a protective metabolite.11 12 13 We do not believe that the lack of increase in interstitial adenosine reported here contradicts this premise. Our results need to be interpreted considering that forearm ischemia was imposed on resting, metabolically inactive skeletal muscle. It is likely that if ischemia was induced in exercising muscle an increase in interstitial adenosine levels would be observed, as suggested by preliminary studies.14
The lack of increase of interstitial adenosine during forearm ischemia could be interpreted as negating the hypothesis that adenosine contributes to reactive hyperemia. This seems unlikely given the substantial evidence from animal experiments supporting a role of adenosine in reactive hyperemia. Nonetheless, we thought it was important to use caffeine withdrawal to test this hypothesis in our model. Numerous animal studies have shown that long-term caffeine administration upregulates adenosine receptors,15 16 17 and we have previously shown potentiation of adenosine actions during caffeine withdrawal in humans.7 The potentiation of reactive hyperemia found in this study supports the role of adenosine in this process.
Taken together, therefore, our results suggest that, at least in the human forearm, the source of adenosine that contributes to reactive hyperemia is located within the intravascular compartment. This conclusion is based on the finding that ischemia selectively increases intravascular levels of adenosine. From our studies we cannot determine the origin of intravascular adenosine or the mechanism by which it mediates reactive hyperemia. Platelet aggregation occurs when a foreign body is placed in a vessel, as could be the case with venous microdialysis. This would result in the release of adenine nucleotides which can be a source of intravascular adenosine18 and that would explain our results. However, platelet aggregation occurs rapidly, within a few minutes or less. Therefore, we would expect an early increase in intravascular adenosine concentrations immediately after the insertion of the microdialysis probe or a gradual increase during the baseline period, neither of which was observed. Furthermore, we found that intravascular thromboxane B2 levels did not increase during ischemia, which indicates the lack of significant platelet activation when intravascular adenosine concentrations were highest.
Because very little if any adenosine injected into the vascular compartment reaches the underlying vascular smooth muscle,6 it has been suggested that adenosine mediates vasodilation by interacting with the endothelium. The nature of such interaction remains controversial. Adenosine-induced vasodilation appears to be mediated by endothelium-derived nitric oxide in some vascular beds,19 20 but whether this occurs in the human forearm is controversial,8 21 and it does not appear to occur in human coronary arteries.22 23 It has also been proposed that adenosine mediates vasodilation through an endothelium-derived hyperpolarizing factor.24 Finally, it is possible that endothelial cells release adenosine not only into the lumen but also into the underlying smooth muscle cells in sufficient quantity to induce local vasodilation but not enough to be detected by our assay.
We have previously proposed that adenosine contributes to the triggering of the exercise pressor reflex, a sympathetically-mediated pressor reflex elicited by ischemic handgrip.25 It is well known that ischemia alone is not sufficient to trigger this reflex26 and the results obtained in this study may provide an explanation for this observation; ischemia alone was not a sufficient stimulus to increase adenosine levels in the interstitium, where afferent fibers involved in the exercise pressor reflex are located.
There are limitations to our study that need to be discussed. With the use of the microdialysis technique we had no difficulty measuring basal resting interstitial levels of adenosine in the skeletal muscle. Our methodology, therefore, was sensitive enough to measure an increase in interstitial adenosine during forearm ischemia. We cannot exclude, however, the possibility of a transient increase in interstitial adenosine during ischemia that, given our sampling period, we were unable to detect. However, it is uncertain if a transient increase would play a role in the subsequent reperfusion period, when reactive hyperemia is observed. Also, our conclusions are based on the assumption that changes in intravascular adenosine measured in an antecubital vein reflect changes at the level of resistance vessels responsible for reactive hyperemia. Currently, it is not possible to test the validity of this assumption because of the risks of introducing a microdialysis probe in the arterial circulation and the inaccessibility of resistance vessels to this or other techniques. It should be noted, however, that similar plasma levels are found in both the arterial and venous circulations.18 Finally, because of the dynamics of our model, it is unlikely that a true equilibrium is reached between both sides of the dialysis membrane. It is important to emphasize, therefore, that the reported dialysate values represent estimates, rather than absolute interstitial adenosine concentrations. We are confident, however, in the direction of the changes observed, particularly when the same technique was applied in the intravascular and interstitial spaces.
Our results are in agreement with those of Kurz et al,27 who studied the cardioprotection elicited by GP531, an analog of acadesine and an adenosine regulating agent that alters adenosine metabolism and promotes its accumulation during ischemia. They found that GP531 improved postischemic myocardial functions in pigs in association with an increase in vascular adenosine concentrations, whereas interstitial adenosine concentrations were no different versus control animals.
In conclusion, our results indicate that adenosine plays a role in the increase in FBF in response to ischemia (reactive hyperemia) in humans. This protective action is mediated by an increase in intravascular adenosine because measurements of interstitial adenosine remained unchanged. We speculate that endothelial cells are an important source of adenosine during ischemia, as previously suggested by Gerlach et al.18
|
Acknowledgments |
|---|
This work was supported in part by NIH grants RR00095 and HL56693.
Received December 9, 1998; first decision January 6, 1999; accepted January 28, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res. 1980;47:807–813.
2.
Dobson JGJr, Rubio R, Berne RM. Role of adenine
nucleotides, adenosine, and inorganic phosphate in
the regulation of skeletal muscle blood flow. Circ Res. 1971;29:375–384.
3.
Belloni FL, Phair RD, Sparks HV. The role of
adenosine in prolonged vasodilation following flow-restricted
exercise of canine skeletal muscle. Circ Res. 1979;44:759–766.
4.
Metting PJ, Weldy DL, Ronau TF, Britton SL. Effect of
aminophylline on hindlimb blood flow autoregulation during increased
metabolism in dogs. J Appl Physiol. 1986;60:1857–1864.
5.
Moser GH, Schrader J, Deussen A. Turnover of
adenosine in plasma of human and dog blood. Am J
Physiol. 1989;256:C799–C806.
6. Nees S, Herzog V, Becker BF, Bock M, Des Rosiers C, Gerlach E. The coronary endothelium: a highly active metabolic barrier for adenosine. Basic Res Cardiol. 1985;80:515–529.[Medline] [Order article via Infotrieve]
7.
Biaggioni I, Paul S, Puckett A, Arzubiaga C. Caffeine
and theophylline as adenosine receptor antagonists
in humans. J Pharmacol Exp Ther. 1991;258:588–593.
8.
Costa F, Biaggioni I. Role of nitric oxide in
adenosine-induced vasodilation in humans.
Hypertension. 1998;31:1061–1064.
9.
Jackson EK, Ohnishi A. Development and application of
a simple microassay for adenosine in rat plasma.
Hypertension. 1987;10:189–197.
10. Christman BW, Lefferts PL, Blair IA, Snapper JR. Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis. 1990;142:1272–1278.[Medline] [Order article via Infotrieve]
11.
Ballard HJ. The influence of lactic acid on
adenosine release from skeletal muscle in anesthetized
dogs. J Physiol. 1991;433:95–108.
12.
Berne RM, Rubio R, Curnish RR. Release of
adenosine from ischemic brain: effect of cerebral
vascular resistance and incorporation into cerebral adenosine
nucleotides. Circ Res. 1974;35:262–271.
13.
Decking UK, Schlieper G, Kroll K, Schrader J.
Hypoxia-induced inhibition of adenosine kinase
potentiates cardiac adenosine release. Circ Res. 1997;81:154–164.
14. Costa F, Davis SN, Biaggioni I. Interstitial adenosine concentrations correlate with sympathetic activation induced by ischemic exercise in humans. Circulation. 1997;96:I-364.
15.
Zhang J, Wells JN. Effects of chronic caffeine
administration on peripheral adenosine receptors.
J Pharmacol Exp Ther. 1990;254:270–276.
16. Green RM, Stiles GL. Chronic caffeine ingestion sensitizes the A1 adenosine receptor-adenylate cyclase system in rat cerebral cortex. J Clin Invest. 1986;77:222–227.
17. Fredholm BB. Adenosine actions and adenosine receptors after 1 week treatment with caffeine. Acta Physiol Scand. 1982;115:283–286.[Medline] [Order article via Infotrieve]
18. Gerlach E, Becker BF, Nees S. Formation of adenosine by vascular endothelium: a homeostatic and antithrombogenic mechanism? In: Gerlach E, Becker BF, eds. Topics and perspectives in adenosine research. Berlin, Germany: Springer-Verlag; 1987:309–320.
19.
Maekawa K, Saito D, Obayashi N, Uchida S, Haraoka S.
Role of endothelium-derived nitric oxide and
adenosine in functional myocardial hyperemia.
Am J Physiol. 1994;267:H166–H173.
20. Zanzinger J, Bassenge E. Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril. Eur Heart J. 1993;14:164–168.
21.
Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA,
Creager MA. Endothelial release of nitric oxide
contributes to the vasodilator effect of adenosine in humans.
Circulation. 1995;92:2135–2141.
22.
Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA,
Cannon RO. Contribution of nitric oxide to metabolic
coronary vasodilation in the human heart.
Circulation. 1995;92:320–326.
23. Shiode N, Morishima N, Nakayama K, Yamagata T, Matsuura H, Kajiyama G. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol. 1996;27:304–310.[Abstract]
24.
Headrick JP, Berne RM.
Endothelium-dependent and -independent relaxations to
adenosine in guinea pig aorta. Am J Physiol. 1990;259:H62–H67.
25. Costa F, Biaggioni I. Role of adenosine in the sympathetic activation produced by isometric exercise in humans. J Clin Invest. 1994;93:1354–1660.
26.
Mark AL, Victor RG, Nerhed C, Wallin BG.
Microneurographic studies of the mechanisms of sympathetic nerve
responses to static exercise in humans. Circ Res. 1985;57:461–469.
27. Kurz MA, Bullough DA, Bugge CJL, Mullane KM, Young MA. Cardioprotection with a novel adenosine regulating agent mediated by intravascular adenosine. Eur J Pharmacol. 1997;322:211–220.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. S. Medow, I. Taneja, and J. M. Stewart Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H425 - H432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Loffler, J. C. Morote-Garcia, S. A. Eltzschig, I. R. Coe, and H. K. Eltzschig Physiological Roles of Vascular Nucleoside Transporters Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1004 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupuis, A. Arsenault, B. Meloche, F. Harel, C. Staniloae, and J. Gregoire Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging: A new marker of coronary artery disease J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1473 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Stewart, M. S. Medow, and L. D. Montgomery Local vascular responses affecting blood flow in postural tachycardia syndrome Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2749 - H2756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Feoktistov, A. E. Goldstein, S. Ryzhov, D. Zeng, L. Belardinelli, T. Voyno-Yasenetskaya, and I. Biaggioni Differential Expression of Adenosine Receptors in Human Endothelial Cells: Role of A2B Receptors in Angiogenic Factor Regulation Circ. Res., March 22, 2002; 90(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F M Mo and H J Ballard The effect of systemic hypoxia on interstitial and blood adenosine, AMP, ADP and ATP in dog skeletal muscle J. Physiol., October 15, 2001; 536(2): 593 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Costa, N. J. Christensen, G. Farley, and I. Biaggioni NO modulates norepinephrine release in human skeletal muscle: implications for neural preconditioning Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1494 - R1498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Costa, A. Diedrich, B. Johnson, P. Sulur, G. Farley, and I. Biaggioni Adenosine, a Metabolic Trigger of the Exercise Pressor Reflex in Humans Hypertension, March 1, 2001; 37(3): 917 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F L. Pasini, P. Capecchi, and T Di Perri Adenosine and chronic ischemia of the lower limbs Vascular Medicine, November 1, 2000; 5(4): 243 - 250. [Abstract] [PDF]
|
|
|
|
 |
|
 W.S. Waring, D.J. Webb, and S.R.J. Maxwell Uric acid as a risk factor for cardiovascular disease QJM, November 1, 2000; 93(11): 707 - 713. [Full Text] [PDF]
|
|
|
|
|
|
F. Costa, J. Heusinkveld, R. Ballog, S. Davis, and I. Biaggioni Estimation of Skeletal Muscle Interstitial Adenosine During Forearm Dynamic Exercise in Humans Hypertension, May 1, 2000; 35(5): 1124 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Feoktistov, A. E. Goldstein, S. Ryzhov, D. Zeng, L. Belardinelli, T. Voyno-Yasenetskaya, and I. Biaggioni Differential Expression of Adenosine Receptors in Human Endothelial Cells: Role of A2B Receptors in Angiogenic Factor Regulation Circ. Res., March 22, 2002; 90(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||